A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.

导出 OA

翻译打印收藏纠错

作者： Stanley B,Cohen ^[1] ; Rieke,Alten ^[2] ; Hideto,Kameda ^[3] ; Tomas,Hala ^[4] ; Sebastiao C,Radominski ^[5] ; Muhammad I,Rehman ^[6] ; Ramesh,Palaparthy ^[7] ; Karl,Schumacher ^[8] ; Susanne,Schmitt ^[8] ; Steven Y,Hua ^[7] ; Claudia,Ianos ^[9] ; K Lea,Sewell ^[10]

作者单位： Metroplex Clinical Research Center, 8144 Walnut Hill Lane, Suite 810, Dallas, TX, 75231, USA. arthdoc@aol.com. ^[1] Schlosspark-Klinik University Medicine, Heubnerweg 2, 14059, Berlin, Germany. ^[2] Toho University Ohashi Medical Center, 2-17-6, Ohashi Muguro-ku, Tokyo, 153-8515, Japan. ^[3] Center for Clinical and Basic Research, Trida Miru 2800, 530 02, Pardubice, Czech Republic. ^[4] Universidade Federal do Paraná, Rua General Carneiro, 181 - Alto da Glória, Curitiba, PR, 80.060-900, Brazil. ^[5] Pfizer Inc., 1 Burtt Road, Andover, MA, 01810, USA. ^[6] Pfizer Inc., 10777 Science Center Drive, CB1/2103, San Diego, CA, 92121, USA. ^[7] Hexal AG, Industriestraße 25, D-83607, Holzkirchen, Germany. ^[8] Pfizer UK, Discovery Park, Ramsgate Road, Sandwich, CT13 9ND, UK. ^[9] Pfizer Inc., 300 Technology Square, Cambridge, MA, 02139, USA. ^[10]

关键词 Biosimilar Dose escalation Infliximab PF-06438179/GP1111 Rheumatoid arthritis